Atara Biotherapeutics Inc (ATRA)
NASDAQ:ATRA
Want to see ATRA full AI Analyst Report?
ATRA Stock Chart & Stats
$15.79
-$1.12(-6.68%)
At close: 4:00 PM EST
$15.79
-$1.12(-6.68%)
Day’s Range― - ―
52-Week Range$3.92 - $19.15
Previous CloseN/A
Volume32.09K
Average Volume (3M)2.85M
Market Cap
$94.70M
Enterprise Value$95.41M
Total Cash (Recent Filing)$8.36M
Total Debt (Recent Filing)$9.08M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 10, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding9,010,172
10 Day Avg. Volume174,914
30 Day Avg. Volume2,854,924
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.89
Price to Sales (P/S)1.88
P/FCF Ratio-4.45
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue4.12
Enterprise Value/Gross Profit4.29
Enterprise Value/Ebitda-17.24
Forecast
1Y Price Target
$13.67Price Target Upside-13.45% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$13.68M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsReported gross margin near 96% implies strong unit economics for Atara’s biologics if commercialized. Durable high margins support long-term profitability per therapy sold and improve the potential return on successful R&D investments, partially offsetting development-stage cost intensity.
Regulatory Pathway Progress For Tab-celPierre Fabre’s Type A meeting outcome — FDA openness to a prespecified single-arm study with historical control — materially improves the structural path to U.S. approval for tab-cel. A realistic regulatory route increases commercialization prospects and potential long-term royalty or revenue streams.
Milestone Timing Relief And Partner SupportExtension of a $9M milestone to 2028 and issuance of a warrant to the royalty fund eases near-term cash obligations and signals continued partner/funder support. This reduces immediate liquidity pressure and lengthens runway to pursue regulatory work and commercialization.
Bears Say
Sharp Revenue ContractionAn ~81% TTM revenue decline erodes operating scale and reflects weak commercial inflows. For a clinical-stage biotech, this magnifies dependency on milestone/collaboration cash and heightens execution risk: sustained low revenue undermines internal funding capacity and strategic optionality.
Persistent Cash BurnConsistent negative operating and free cash flow (~-$25.9M TTM) creates a structural funding need. Persistent burn pressures capital raises, dilutes shareholders, limits ability to self-fund trials or commercialization, and increases execution risk absent partner milestones or new financing.
Nasdaq Non-compliance / Delisting RiskA Nasdaq non-compliance notice threatens liquidity, institutional access, and investor visibility if delisted. Over the coming months this structural listing risk can hinder capital raises, worsen financing terms, and constrain long-term strategic partnerships unless compliance is regained.
Atara Biotherapeutics News
ATRA FAQ
What was Atara Biotherapeutics Inc’s price range in the past 12 months?
Atara Biotherapeutics Inc lowest stock price was $3.92 and its highest was $19.14 in the past 12 months.
What is Atara Biotherapeutics Inc’s market cap?
Atara Biotherapeutics Inc’s market cap is $94.70M.
When is Atara Biotherapeutics Inc’s upcoming earnings report date?
Atara Biotherapeutics Inc’s upcoming earnings report date is Aug 10, 2026 which is in 71 days.
How were Atara Biotherapeutics Inc’s earnings last quarter?
Atara Biotherapeutics Inc released its earnings results on May 12, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.04.
Is Atara Biotherapeutics Inc overvalued?
According to Wall Street analysts Atara Biotherapeutics Inc’s price is currently Overvalued.
Does Atara Biotherapeutics Inc pay dividends?
Atara Biotherapeutics Inc does not currently pay dividends.
What is Atara Biotherapeutics Inc’s EPS estimate?
Atara Biotherapeutics Inc’s EPS estimate is -0.32.
How many shares outstanding does Atara Biotherapeutics Inc have?
Atara Biotherapeutics Inc has 9,010,172 shares outstanding.
What happened to Atara Biotherapeutics Inc’s price movement after its last earnings report?
Atara Biotherapeutics Inc reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went up 6.83%.
Which hedge fund is a major shareholder of Atara Biotherapeutics Inc?
Currently, no hedge funds are holding shares in ATRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atara Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.67 (-13.45% Downside)
$13.67 (-13.45% Downside)
Hedge Fund Trend
Decreased
By 70.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
34.74%
12-Months-Change
Fundamentals
Return on Equity
25.68%
Trailing 12-Months
Asset Growth
-67.77%
Trailing 12-Months
Company Description
Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
ATRA Stock 12 Month Forecast
Average Price Target
$13.67
▼(-13.45% Downside)
Technical Analysis
Ownership Overview
36.00% Insiders
5.52% Mutual Funds
18.18% Other Institutional Investors
37.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---